Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP870158.RAwfWhoKMhYWNr4u-ZZKRqXD4pmang_bHR9pSbuI2bq-0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP870158.RAwfWhoKMhYWNr4u-ZZKRqXD4pmang_bHR9pSbuI2bq-0130_assertion type Assertion NP870158.RAwfWhoKMhYWNr4u-ZZKRqXD4pmang_bHR9pSbuI2bq-0130_head.
- NP870158.RAwfWhoKMhYWNr4u-ZZKRqXD4pmang_bHR9pSbuI2bq-0130_assertion description "[Liver disease progression is accompanied by a proportional, drastic reduction in the magnitude of reversible inhibitory drug interactions due to decreased hepatic uptake of the inhibitor and reduced CYP expression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP870158.RAwfWhoKMhYWNr4u-ZZKRqXD4pmang_bHR9pSbuI2bq-0130_provenance.
- NP870158.RAwfWhoKMhYWNr4u-ZZKRqXD4pmang_bHR9pSbuI2bq-0130_assertion evidence source_evidence_literature NP870158.RAwfWhoKMhYWNr4u-ZZKRqXD4pmang_bHR9pSbuI2bq-0130_provenance.
- NP870158.RAwfWhoKMhYWNr4u-ZZKRqXD4pmang_bHR9pSbuI2bq-0130_assertion SIO_000772 20604736 NP870158.RAwfWhoKMhYWNr4u-ZZKRqXD4pmang_bHR9pSbuI2bq-0130_provenance.
- NP870158.RAwfWhoKMhYWNr4u-ZZKRqXD4pmang_bHR9pSbuI2bq-0130_assertion wasDerivedFrom befree-20140225 NP870158.RAwfWhoKMhYWNr4u-ZZKRqXD4pmang_bHR9pSbuI2bq-0130_provenance.
- NP870158.RAwfWhoKMhYWNr4u-ZZKRqXD4pmang_bHR9pSbuI2bq-0130_assertion wasGeneratedBy ECO_0000203 NP870158.RAwfWhoKMhYWNr4u-ZZKRqXD4pmang_bHR9pSbuI2bq-0130_provenance.